Format

Send to

Choose Destination
Cancer Discov. 2017 Jul 20. doi: 10.1158/2159-8290.CD-17-0343. [Epub ahead of print]

Tumor Evolution as a Therapeutic Target.

Author information

1
Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO), IRCCS, Candiolo, Torino, Italy.
2
University College London Cancer Institute and The Francis Crick Institute, London, United Kingdom.
3
Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO), IRCCS, Candiolo, Torino, Italy. alberto.bardelli@unito.it.
4
Department of Oncology, University of Torino, Torino, Italy.

Abstract

Recent technological advances in the field of molecular diagnostics (including blood-based tumor genotyping) allow the measurement of clonal evolution in patients with cancer, thus adding a new dimension to precision medicine: time. The translation of this new knowledge into clinical benefit implies rethinking therapeutic strategies. In essence, it means considering as a target not only individual oncogenes but also the evolving nature of human tumors. Here, we analyze the limitations of targeted therapies and propose approaches for treatment within an evolutionary framework.Significance: Precision cancer medicine relies on the possibility to match, in daily medical practice, detailed genomic profiles of a patient's disease with a portfolio of drugs targeted against tumor-specific alterations. Clinical blockade of oncogenes is effective but only transiently; an approach to monitor clonal evolution in patients and develop therapies that also evolve over time may result in improved therapeutic control and survival outcomes. Cancer Discov; 7(8); 1-13. ©2017 AACR.

PMID:
28729406
DOI:
10.1158/2159-8290.CD-17-0343
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center